TACE and other ADAM proteases as targets for drug discovery.

Tumor necrosis factor (TNF)-converting enzyme (TACE) and other ADAM proteases (those that contain a disintegrin and a metalloprotease domain) have emerged as potential therapeutic targets in the areas of arthritis, cancer, diabetes and HIV cachexia. TACE is the first ADAM protease to process the known physiological substrate and inflammatory cytokine, membrane-bound precursor-TNF-alpha, to its mature soluble form. Subsequently, TACE was shown to be required for several different processing events such as tumor growth factor-alpha (TGF-alpha) precursor and amyloid precursor protein (APP) cleavage. With the recent discoveries of the proteolytic specificities of other ADAM family members, the information surrounding these metalloproteases is expanding at an exponential rate. This review focuses on TACE and other family members with known proteolytic function as well as the inhibitors of this class of enzyme.

[1]  E. Engvall,et al.  Binding of ADAM12, a Marker of Skeletal Muscle Regeneration, to the Muscle-specific Actin-binding Protein, α-Actinin-2, Is Required for Myoblast Fusion* , 2000, The Journal of Biological Chemistry.

[2]  G. Rubin,et al.  The cell surface metalloprotease/disintegrin Kuzbanian is required for axonal extension in Drosophila. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[3]  T. Wolfsberg,et al.  ADAMs in fertilization and development. , 1996, Developmental biology.

[4]  P. Genever,et al.  Localization of ADAM10 and Notch receptors in bone. , 1999, Bone.

[5]  A Cumano,et al.  A novel proteolytic cleavage involved in Notch signaling: the role of the disintegrin-metalloprotease TACE. , 2000, Molecular cell.

[6]  H. Birkedal‐Hansen,et al.  The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[7]  T. Oltersdorf,et al.  Cleavage of amyloid beta peptide during constitutive processing of its precursor. , 1990, Science.

[8]  C. Blobel,et al.  Metalloprotease-disintegrins: modular proteins capable of promoting cell-cell interactions and triggering signals by protein-ectodomain shedding. , 1999, Journal of cell science.

[9]  P. Slocombe,et al.  Meltrin γ (ADAM-9) mediates cellular adhesion through α6β1 integrin, leading to a marked induction of fibroblast cell motility , 2000 .

[10]  R. Huber,et al.  Refined 2.0 A X-ray crystal structure of the snake venom zinc-endopeptidase adamalysin II. Primary and tertiary structure determination, refinement, molecular structure and comparison with astacin, collagenase and thermolysin. , 1994, Journal of molecular biology.

[11]  E. Meyer,et al.  Structures of adamalysin II with peptidic inhibitors. Implications for the design of tumor necrosis factor α convertase inhibitors , 1998, Protein science : a publication of the Protein Society.

[12]  E. Wagner,et al.  Strain-dependent epithelial defects in mice lacking the EGF receptor. , 1995, Science.

[13]  F. Loechel,et al.  ADAM 12, a Disintegrin Metalloprotease, Interacts with Insulin-like Growth Factor-binding Protein-3* , 2000, The Journal of Biological Chemistry.

[14]  E. Engvall,et al.  Human ADAM 12 (Meltrin α) Is an Active Metalloprotease* , 1998, The Journal of Biological Chemistry.

[15]  M. Lambert,et al.  Specific Sequence Elements Are Required for the Expression of Functional Tumor Necrosis Factor-α-converting Enzyme (TACE)* , 1999, The Journal of Biological Chemistry.

[16]  X. Zhang,et al.  Bioactive conformation of a potent stromelysin inhibitor determined by X-nucleus filtered and multidimensional NMR spectroscopy. , 1997, Bioorganic & medicinal chemistry.

[17]  J. White,et al.  Sequence-specific interaction between the disintegrin domain of mouse ADAM 3 and murine eggs: role of beta1 integrin-associated proteins CD9, CD81, and CD98. , 2001, Molecular biology of the cell.

[18]  A. H. Drummond,et al.  Recent advances in matrix metalloproteinase inhibitor research , 1996 .

[19]  E. Kojro,et al.  Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[20]  E. Nice,et al.  Mice with a null mutation of the TGFα gene have abnormal skin architecture, wavy hair, and curly whiskers and often develop corneal inflammation , 1993, Cell.

[21]  D. Price,et al.  Evidence that beta-amyloid protein in Alzheimer's disease is not derived by normal processing. , 1990, Science.

[22]  G. Rubin,et al.  Kuzbanian Controls Proteolytic Processing of Notch and Mediates Lateral Inhibition during Drosophila and Vertebrate Neurogenesis , 1997, Cell.

[23]  P. Cohen,et al.  Novel aspects of the insulin-like growth factor binding proteins. , 1999, Molecular genetics and metabolism.

[24]  E. Engvall,et al.  A Novel, Secreted Form of Human ADAM 12 (Meltrin α) Provokes Myogenesis in Vivo * , 1998, The Journal of Biological Chemistry.

[25]  2 Å X‐ray structure of adamalysin II complexed with a peptide phosphonate inhibitor adopting a retro‐binding mode , 1997, FEBS letters.

[26]  R. Derynck,et al.  Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor , 1995, Nature.

[27]  R. Huber,et al.  Crystal structure of the catalytic domain of human tumor necrosis factor-alpha-converting enzyme. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[28]  T G Wolfsberg,et al.  ADAM, a novel family of membrane proteins containing A Disintegrin And Metalloprotease domain: multipotential functions in cell-cell and cell- matrix interactions , 1995, The Journal of cell biology.

[29]  D. Bradshaw,et al.  Metalloproteinases as Targets for Anti-Inflammatory Drugs , 1999, Progress in Inflammation Research.

[30]  R. Black,et al.  Unaltered Cleavage and Secretion of Angiotensin-converting Enzyme in Tumor Necrosis Factor-α-converting Enzyme-deficient Mice* , 1999, The Journal of Biological Chemistry.

[31]  P. Glynn,et al.  Molecular cloning of MADM: a catalytically active mammalian disintegrin-metalloprotease expressed in various cell types. , 1996, The Biochemical journal.

[32]  R. Black,et al.  Functional Analysis of the Domain Structure of Tumor Necrosis Factor-α Converting Enzyme* , 2000, The Journal of Biological Chemistry.

[33]  L. Bélec,et al.  Increased tumor necrosis factor-alpha serum levels in patients with HIV wasting syndrome and euthyroid sick syndrome. , 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[34]  F. Loechel,et al.  Trafficking of human ADAM 12-L: retention in the trans-Golgi network. , 2000, Biochemical and biophysical research communications.

[35]  R. Black,et al.  ADAMs: focus on the protease domain. , 1998, Current opinion in cell biology.

[36]  M. T. Brewer,et al.  Identification and Characterization of a Pro-tumor Necrosis Factor-α-processing Enzyme from the ADAM Family of Zinc Metalloproteases* , 1997, The Journal of Biological Chemistry.

[37]  R. Fässler,et al.  The Cysteine-Rich Domain of Human Adam 12 Supports Cell Adhesion through Syndecans and Triggers Signaling Events That Lead to β1 Integrin–Dependent Cell Spreading , 2000, The Journal of cell biology.

[38]  J. Fox,et al.  Structural interaction of natural and synthetic inhibitors with the venom metalloproteinase, atrolysin C (form d). , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[39]  C. Blobel,et al.  Evidence for an interaction of the metalloprotease-disintegrin tumour necrosis factor alpha convertase (TACE) with mitotic arrest deficient 2 (MAD2), and of the metalloprotease-disintegrin MDC9 with a novel MAD2-related protein, MAD2beta. , 1999, The Biochemical journal.

[40]  L. Lum,et al.  Evidence for a Role of a Tumor Necrosis Factor-α (TNF-α)-converting Enzyme-like Protease in Shedding of TRANCE, a TNF Family Member Involved in Osteoclastogenesis and Dendritic Cell Survival* , 1999, The Journal of Biological Chemistry.

[41]  C. Blobel,et al.  Intracellular maturation and localization of the tumour necrosis factor alpha convertase (TACE). , 2000, The Biochemical journal.

[42]  R. Black,et al.  Isolation of two novel metalloproteinase-disintegrin (ADAM) cDNAs that show testis-specific gene expression. , 1999, Biochemical and biophysical research communications.

[43]  P. Croucher,et al.  Expression of members of the novel membrane linked metalloproteinase family ADAM in cells derived from a range of haematological malignancies. , 1997, Biochemical and biophysical research communications.

[44]  G. Devi,et al.  Differential Effects of Insulin-Like Growth Factor (IGF)-Binding Protein-3 and Its Proteolytic Fragments on Ligand Binding, Cell Surface Association, and IGF-I Receptor Signaling* * This research was supported by US Army Grants DAMD17-991-9522 (to G.R.D.) and DAMD17-96-1-6204 and DAMD17-96-1-7204 (t , 2000, Endocrinology.

[45]  R. Maciewicz,et al.  New alpha-substituted succinate-based hydroxamic acids as TNFalpha convertase inhibitors. , 1999, Journal of medicinal chemistry.

[46]  P. Primakoff,et al.  The ADAM gene family: surface proteins with adhesion and protease activity. , 2000, Trends in genetics : TIG.

[47]  Y. Takada,et al.  Specific Interaction of the Recombinant Disintegrin-like Domain of MDC-15 (Metargidin, ADAM-15) with Integrin αvβ3* , 1998, The Journal of Biological Chemistry.

[48]  L. Liotta,et al.  Batimastat, a potent matrix mealloproteinase inhibitor, exhibits an unexpected mode of binding. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[49]  N. Hooper,et al.  The secretases that cleave angiotensin converting enzyme and the amyloid precursor protein are distinct from tumour necrosis factor‐α convertase , 1998, FEBS letters.

[50]  Sudhir V. Shah,et al.  The new kids on the block: ADAMTSs, potentially multifunctional metalloproteinases of the ADAM family. , 2000, The Journal of clinical investigation.

[51]  David C. Lee,et al.  TGFα deficiency results in hair follicle and eye abnormalities in targeted and waved-1 mice , 1993, Cell.

[52]  M. Overgaard,et al.  Regulation of Human ADAM 12 Protease by the Prodomain , 1999, The Journal of Biological Chemistry.

[53]  J. Martel-Pelletier,et al.  IGF/IGFBP axis in cartilage and bone in osteoarthritis pathogenesis , 1998, Inflammation Research.

[54]  J. Treanor,et al.  Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. , 1999, Science.

[55]  Nicole Nelson,et al.  A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells , 1997, Nature.

[56]  M. Lambert,et al.  The Tumor Necrosis Factor-α Converting Enzyme , 2000 .

[57]  J. White,et al.  Sequence-specific Interaction between the Disintegrin Domain of Mouse ADAM 2 (Fertilin β) and Murine Eggs , 2000, The Journal of Biological Chemistry.

[58]  N. Mckie,et al.  The metallo-disintegrin ADAM10 (MADM) from bovine kidney has type IV collagenase activity in vitro. , 1998, Biochemical and biophysical research communications.

[59]  Paul S. Charifson,et al.  Practical Application of Computer-Aided Drug Design , 1997 .

[60]  K. Herrup,et al.  Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. , 1995, Science.

[61]  Raphael Kopan,et al.  A ligand-induced extracellular cleavage regulates gamma-secretase-like proteolytic activation of Notch1. , 2000, Molecular cell.

[62]  T. Wolfsberg,et al.  ADAM, a widely distributed and developmentally regulated gene family encoding membrane proteins with a disintegrin and metalloprotease domain. , 1995, Developmental biology.

[63]  A. H. Drummond,et al.  Preclinical and Clinical Studies of MMP Inhibitors in Cancer , 1999, Annals of the New York Academy of Sciences.

[64]  Joseph D. Buxbaum,et al.  Evidence That Tumor Necrosis Factor α Converting Enzyme Is Involved in Regulated α-Secretase Cleavage of the Alzheimer Amyloid Protein Precursor* , 1998, The Journal of Biological Chemistry.

[65]  D. Small,et al.  Regulation of APP cleavage by α‐, β‐ and γ‐secretases , 2000 .

[66]  Y. Nabeshima,et al.  A metalloprotease-disintegrin participating in myoblast fusion , 1995, Nature.

[67]  G. Wu,et al.  Cutting edge: a dominant negative form of TNF-alpha converting enzyme inhibits proTNF and TNFRII secretion. , 1999, Journal of immunology.

[68]  C. Blobel,et al.  Interaction of the Metalloprotease Disintegrins MDC9 and MDC15 with Two SH3 Domain-containing Proteins, Endophilin I and SH3PX1* , 1999, The Journal of Biological Chemistry.

[69]  S. Rose-John,et al.  Shedding of interleukin-6 receptor and tumor necrosis factor alpha. Contribution of the stalk sequence to the cleavage pattern of transmembrane proteins. , 2000, European journal of biochemistry.

[70]  G. Weskamp,et al.  MDC9, a widely expressed cellular disintegrin containing cytoplasmic SH3 ligand domains , 1996, The Journal of cell biology.

[71]  David C. Lee,et al.  An essential role for ectodomain shedding in mammalian development. , 1998, Science.

[72]  G. Rubin,et al.  KUZ, a Conserved Metalloprotease-Disintegrin Protein with Two Roles in Drosophila Neurogenesis , 1996, Science.

[73]  Alfredo G. Tomasselli,et al.  Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity , 1999, Nature.

[74]  D. Sheppard,et al.  RGD-independent Binding of Integrin α9β1 to the ADAM-12 and -15 Disintegrin Domains Mediates Cell-Cell Interaction* , 2000, The Journal of Biological Chemistry.

[75]  R. Barbour,et al.  Purification and cloning of amyloid precursor protein β-secretase from human brain , 1999, Nature.

[76]  R. Black,et al.  Stimulation-induced Down-regulation of Tumor Necrosis Factor-α Converting Enzyme* , 2000, The Journal of Biological Chemistry.

[77]  A. Gaultier,et al.  PACSIN2 is a regulator of the metalloprotease/disintegrin ADAM13. , 2000, Developmental biology.

[78]  G. Weskamp,et al.  Metalloprotease-Disintegrin MDC9: Intracellular Maturation and Catalytic Activity* , 1999, The Journal of Biological Chemistry.

[79]  P. Rakic,et al.  Processing of the notch ligand delta by the metalloprotease Kuzbanian. , 1999, Science.

[80]  M. Ohashi,et al.  KB-R7785, a novel matrix metalloproteinase inhibitor, exerts its antidiabetic effect by inhibiting tumor necrosis factor-alpha production. , 1997, Life sciences.

[81]  P. Slocombe,et al.  Meltrin gamma(ADAM-9) mediates cellular adhesion through alpha(6)beta(1 )integrin, leading to a marked induction of fibroblast cell motility. , 2000, Journal of cell science.

[82]  J. Buxbaum,et al.  Tumor Necrosis Factor-α-converting Enzyme Is Required for Cleavage of erbB4/HER4* , 2000, The Journal of Biological Chemistry.

[83]  Mark Whittaker,et al.  Matrix metalloproteinase inhibitors 1998 , 1998 .

[84]  A. Zolkiewska,et al.  Metalloprotease-disintegrin ADAM 12 binds to the SH3 domain of Src and activates Src tyrosine kinase in C2C12 cells. , 2000, The Biochemical journal.

[85]  J. Laydon,et al.  Anti-arthritic activity of hydroxamic acid-based pseudopeptide inhibitors of matrix metalloproteinases and TNFα processing , 1997, Inflammation Research.

[86]  E. Mekada,et al.  A metalloprotease–disintegrin, MDC9/meltrin‐γ/ADAM9 and PKCδ are involved in TPA‐induced ectodomain shedding of membrane‐anchored heparin‐binding EGF‐like growth factor , 1998, The EMBO journal.

[87]  C. López-Otín,et al.  ADAM 23/MDC3, a Human Disintegrin That Promotes Cell Adhesion via Interaction with the αvβ3 Integrin through an RGD-independent Mechanism , 2000 .

[88]  A. Goate,et al.  A common enzyme connects notch signaling and Alzheimer's disease. , 2000, Genes & development.

[89]  M. Lambert,et al.  Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α , 1997, Nature.

[90]  R. Doms,et al.  Protein Kinase C-dependent α-Secretase Competes with β-Secretase for Cleavage of Amyloid-β Precursor Protein in the Trans-Golgi Network* , 2000, The Journal of Biological Chemistry.

[91]  J G Flanagan,et al.  Regulated cleavage of a contact-mediated axon repellent. , 2000, Science.

[92]  M. Gerhart,et al.  Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing , 1994, Nature.

[93]  S. Narula,et al.  Purification of ADAM 10 from bovine spleen as a TNFα convertase , 1997 .

[94]  T. Wolfsberg,et al.  A potential fusion peptide and an integrin ligand domain in a protein active in sperm–egg fusion , 1992, Nature.

[95]  A. Bernstein,et al.  Presenilins are required for γ-secretase cleavage of β-APP and transmembrane cleavage of Notch-1 , 2000, Nature Cell Biology.